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Erythropoietin Improves Long-Term Outcomes in Patients with 
Acute Kidney Injury after Coronary Artery Bypass Grafting
Previous studies reported the beneficial effect of erythropoietin (EPO) in acute injuries. We 
followed patients with and without acute kidney injury (AKI) after coronary artery bypass 
grafting (CABG) and evaluated the effect of EPO on long-term outcome. We also assessed 
the efficacy of urinary neutrophil gelatinase-associated lipocalin (uNGAL) as a predictive 
marker of AKI. Seventy-one patients scheduled for elective CABG were randomly given 
either 300 U/kg of EPO or saline before CABG. The primary outcome was AKI, and the 
secondary outcome was the all-cause-mortality and composite of all-cause-mortality and 
end stage renal disease (ESRD). Twenty-one patients had AKI, 14 (66.7%) in the placebo 
group and 7 (33.3%) in the EPO group (P = 0.05). Also, uNGAL was higher in the patients 
with AKI than in those without AKI at baseline, 2, 4, 24, and 72 hr after CABG (P = 0.011). 
Among patients with AKI, 2-week creatinine (Cr) was not different from baseline Cr in the 
EPO group, but 2-week Cr was significantly higher than baseline Cr in the placebo group  
(P = 0.009). All-cause-mortality (P = 0.022) and the composite of all-cause-mortality and 
ESRD (P = 0.003) were reduced by EPO. EPO reduces all-cause-mortality and ESRD in 
patients with AKI, largely due to the beneficial effect of EPO on recovery after AKI.
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INTRODUCTION
Erythropoietin (EPO) is the hormone that regulates blood cell 
production and is mainly produced by peritubular fibroblasts 
of the renal cortex and outer medulla (1). In the presence of 
ischemic or hypoxic insult, endogenous production of EPO is 
increased in the kidney, liver, and brain (2). EPO facilitates oxy-
gen delivery and erythropoiesis and reduces apoptosis, oxida-
tive stress, and inflammation (4, 5). Therefore, the hypothesis 
has emerged that pre-conditioning or pre-treatment of EPO   
reduces the severity of injuries that typically mediate apoptosis, 
oxidative stress, and inflammation. In addition, it has been re-
ported that pre-conditioning or pre-treatment of EPO has pro-
tective effects in the context of injury to the brain, heart, lung 
and kidney (6-12). 
  We reported that EPO administration could prevent acute 
kidney injury (AKI) in patients undergoing coronary artery by-
pass grafting (CABG) (8). Other studies also reported the bene-
ficial effect of EPO in acute injury or short-term outcomes (6-9), 
however, few studies evaluated the long-term outcome of EPO 
administration. Recent studies reported that AKI was a risk fac-
tor for long-term mortality, end-stage renal disease (ESRD), and 
hospitalization (13, 14). We followed patients with and without 
AKI after CABG and evaluated the association between AKI and 
mortality or ESRD.
  Urinary neutrophil gelatinase-associated lipocalin (uNGAL) 
has been recently studied as a biomarker for the prediction of 
AKI, mortality and ESRD (15, 16). Serum creatinine (Cr) has sev-
eral limitations because of its dependence on age, sex and mus-
cle mass. In addition, it has limited usefulness in the early detec-
tion of AKI because it does not accurately reflect renal function 
during the non-steady state of AKI (17). NGAL is highly up-reg-
ulated after renal tubular injury and has been investigated in 
different clinical settings of AKI, such as CABG, coronary angi-
ography and critical illness (15, 16, 18). Urinary NGAL concen-
tration was increased several hours after CABG (15, 16). How-
ever, it has not been determined whether baseline NGAL is as-
sociated with AKI and long-term outcome. 
  In this study, we investigated the effect of EPO on mortality 
or the development of ESRD in patients undergoing CABG. We 
also evaluated whether urine NGAL could predict AKI in these 
patients.
MATERIALS AND METHODS
Patients
This investigation is a prospective, randomized, double-blind, 
placebo-controlled trial performed at Seoul National University 
Bundang Hospital. We included patients over 18 yr of age who 
were scheduled for elective CABG. Emergent CABG, AKI before Oh SW, et al.  •  Erythropoietin and Mortality in Acute Kidney Injury 
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randomization, chronic renal replacement therapy, uncontrolled 
hypertension, known allergy or hypersensitivity to EPO, use of 
nephrotoxic drugs within 3 days of the planned operation or 
use of EPO prior to CABG were criteria for exclusion. This study 
is a follow-up of the prospective trial published in 2009 (8). 
Study protocol
The patients received either EPO (EPO group) or saline (placebo 
group) before CABG. A research coordinator performed random-
ization and prepared the study drugs: 300 U/kg of EPO (Recor-
mon, Roche, Basel, Switzerland) was administered intravenous-
ly immediately following induction of anesthesia in the EPO 
group, and normal saline was administered in the placebo group. 
Healthcare clinicians, investigators, and patients were blinded 
to treatment assignment. A randomization code list with a block 
size of two was generated by Medical Research Collaborating 
Center Seoul National University Hospital. The randomization 
was stratified by serum Cr (< 1.5 and  ≥ 1.5 mg/dL) and use of 
cardiopulmonary bypass during surgery. Treatments were allo-
cated to patients through the Internet in accordance with the pre-
defined randomization list (1:1 ratio for EPO or placebo group).
  Blood samples were obtained preoperatively (‘baseline’) and 
at 4, 12, 24, 72, and 120 hr postoperatively. Urine samples were 
obtained at 2, 4, 24, and 72 hr postoperatively. Serum Cr was 
measured using the modified Jaffe method on a Toshiba 200FR 
Analyzer (Toshiba, Tokyo, Japan). Estimated glomerular filtra-
tion rate (eGFR) was calculated using the Modification of Diet 
in Renal Disease study equation. 
ELISA for NGAL quantification
Urine NGAL ELISA was performed using a commercially avail-
able assay (NGAL ELISA Kit 036; AntibodyShop, Grusbakken, 
Denmark). This assay was performed according to the manu-
facturer’s protocol. Briefly, 100 μL of NGAL standards or diluted 
patient specimen was applied on to the precoated microwells in 
duplicate. Microwells were subsequently incubated for 1 hr at 
room temperature. In succession, 100 μL of biotinylated NGAL 
antibody and 100 μL of HRP-streptavidin were incubated in the 
wells for 1 hr, respectively. TMB substrate was incubated for       
10 min in the dark before the addition of stop solution. Finally, 
optical densities were measured at 450 nm wavelength with a 
reference reading at 620 nm in blank wells by microplate reader. 
The laboratory investigators were blinded to the specimen sourc-
es and clinical outcomes.
 
Outcomes
The primary outcome is acute kidney injury. The diagnostic cri-
teria for AKI is followed by an absolute increase in the serum Cr 
concentration  ≥ 0.3 mg/dL from baseline,  ≥ 50% increase in 
the serum Cr concentration in the first 72 hr after CABG, or less 
than 0.5 mL/kg per hour of oliguria for more than six hours.
  The secondary outcome is the mortality and the composite 
outcome of ESRD and mortality. We combined the mortality 
data from Statistics Korea (19) and the ESRD incidence from 
the ESRD registry of the Korean Society of Nephrology (20) with 
our dataset using each individual’s unique identifier as the pri-
mary key element. We obtained the mortality and ESRD data 
collected prior to December 2009. The cause of death could not 
be specified and only all-cause-mortality was examined because 
the data did not specify individual causes of death.
Statistical analysis
Descriptive statistics were reported as the median [25%-75%] or 
the mean ± standard deviation for continuous variables or fre-
quency for categorical variables. Differences in continuous vari-
ables were analyzed by a Mann-Whitney U test for unequal vari-
ance or by two-tailed, unpaired t-tests for equal variance and by 
chi-square tests for categorical variables. Paired t-test was used 
to evaluate the relationship between 2-week Cr or 72-hr Cr and 
baseline Cr. We compared the cumulative incidence of ESRD 
and all-cause mortality among patients, who were categorized 
into four groups according to AKI status or EPO administration 
by a log-rank test. Two-sided P values were reported with 0.05 
taken as the level of statistical significance. All analyses were 
conducted using SPSS (version 15.0, SPSS, Chicago, IL, USA).
Ethics statement
The protocol was approved by the institutional review board of 
Seoul National University Bundang Hospital (No. B-0608/036-
004). This trial was registered at ClinicalTrials.gov (www.clini-
caltrial.gov), No. NCT 00654992. All of the subjects submitted 
informed consent for this study.
RESULTS
Baseline characteristics 
Seventy-one patients were randomized to receive EPO (n = 36) 
or saline (n = 35) and completed the trial from September 2006 
to February 2008. The similarities of baseline characteristics and 
intra-operative data between EPO and placebo groups were pre-
viously mentioned (8). The mean age of participants was 66.7 ±  
9.8 yr. In total, 53 (74.6%) patients were male, 53 (74.6%) patients 
had hypertension, 30 (42.3%) were diabetic, 11 (15.5%) had pe-
ripheral vascular diseases, mean estimated GFR was 69.7 ± 22.3 
mL/min/1.73 m
2 and six patients had a left ventricular ejection 
fraction (LVEF) less than 40%.
  We reanalyzed data stratified by the existence of AKI in the 
EPO and placebo groups. Among 71 patients, 21 patients had 
AKI; 14 (66.7%) in the placebo group and 7 (33.3%) in the EPO 
group (P = 0.05). In the placebo group, the patients with AKI 
were older than those without AKI. In the EPO group, the pa-
tients with AKI had higher BMI (23.6 [22.4-25.8] vs 26.7 [25.8-28.7]), Oh SW, et al.  •  Erythropoietin and Mortality in Acute Kidney Injury 
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higher baseline urine NGAL (4.7 [1.8-10.7] ng/mL vs 13.0 [7.9-
10.7] ng/mL) and lower eGFR (66.5 [56.5-77.9] mL/min/1.73 m
2 
vs 57.1 [44.7-62.2] mL/min/1.73 m
2) than those without AKI 
had. Otherwise, no significant differences were observed when 
patients were stratified by the existence of AKI in both the pla-
cebo and EPO groups. Among patients with AKI, higher BMI 
was noted in EPO group than in the placebo group (Table 1). 
Change of urine NGAL and the development of AKI
The baseline urine NGAL was significantly higher in the patients 
with AKI compared to those without AKI. In 50 patients who did 
not have AKI, the baseline urine NGAL was 5.0 [2.2-14.2] μg/L, 
which was significantly lower than the value observed in 21 pa-
tients who had AKI (11.3 [7.5-90.7] μg/L) (P = 0.009). At 2, 4, 24, 
and 72 hr after CABG, higher concentrations of urine NGAL 
were noted in patients with AKI (Table 2). 
  With respect to the baseline urine NGAL, the area under the 
ROC curve (AUC) was 0.713 (95% confidence interval [CI], 0.586-
0.841) for the prediction of AKI. A cutoff of 5 ng/mL showed a 
sensitivity of 0.89, a specificity of 0.48, and a negative predictive 
value of 0.91. For urine NGAL collected 2 hr after CABG, the AUC 
for the prediction of AKI was 0.804 (95% CI, 0.696-0.911). Being 
divided by the level of baseline urine NGAL, the patients with 
≥ 5 ng/mL of urine NGAL had less AKI than those with  < 5 ng/
mL of urine NGAL (16 patients [41.0%] vs 2 patients [8.7%], P =  
0.007). 
Recovery from acute kidney injury
In 21 patients with AKI, one patient met urine output criteria 
and one patient met both Cr and urine output criteria. We ana-
lyzed serum Cr at 2 weeks after CABG (2-week Cr) to assess the 
severity and duration of AKI (Table 3). In patients with AKI, the 
mean value of 72-hr Cr was 2.02 ± 1.09 in the placebo group and 
2.16 ± 0.56 in the EPO group. The mean of 2-week Cr was 1.63 ±  
0.60 and 1.51 ± 0.48, respectively. The 72-hr Cr values were sig-
nificantly higher than baseline Cr values in both groups (P =  
0.003). In the EPO group, 2-week Cr was not significantly higher 
than the baseline Cr (P = 0.578). However, 2-week Cr in the pla-
cebo group remained higher than the baseline Cr (P = 0.009) 
(Fig. 1). 
Outcome of mortality and ESRD
Over 27.9 ± 8.8 months of follow-up, the overall mortality rate 
was 14.1%. Seven patients in the placebo group (20.0%) died;       
3 patients (8.3%) in the EPO group died. ESRD developed in only 
1 (1.4%) patient, who was in the placebo group. Higher mortali-
ties or higher incidence of ESRD were observed during follow-
up in patients who had AKI (log-rank test, P = 0.031). 
  We grouped participants according to the development of 
Table 1. Baseline characteristics
Parameters
Placebo EPO
no AKI AKI no AKI AKI
Patients (n) 21 (42.0) 14 (66.7) 29 (58.0) 7 (33.3)
Age (yr)*   68.0 [62.0-72.0]   73.0 [69.0-77.5]      62 [56.5-72.5]   70.0 [62.0-75.0]
Men (%) 14 (66.7)   9 (64.3) 26 (89.7) 4 (57.1)
BMI
†,‡   23.5 [22.2-25.8]   22.7 [21.4-24.2]   23.6 [22.4-25.8]   26.7 [25.8-28.7] 
SBP (mmHg)     119.5 [106.8-131.3]     121.0 [110.5-130.0]   114.0 [93.0-115.0]     115.0 [102.5-127.5]
DBP (mmHg)   62.5 [60.0-67.0]   68.0 [61.5-75.0]   70.0 [66.0-77.0]   67.0 [59.0-73.5]
Serum Cr (mg/dL) 1.0 [0.9-1.1] 1.2 [0.9-1.5] 1.1 [1.0-1.3] 1.4 [1.2-1.8]
eGFR
†,‡ (mL/min/1.73 m
2)   83.9 [67.0-97.6]   60.0 [47.2-87.9]   66.5 [56.5-77.9]   57.1 [44.7-62.2]
uNGAL (ng/mL)
†   6.7 [3.0-13.9] 10.6 [6.3-20.0]   4.7 [1.8-10.7] 13.0 [7.9-10.7]
Hemoglobin (g/dL)   12.8 [12.0-13.4]   13.2 [10.6-14.0]   13.5 [12.5-14.2]   14.3 [10.9-16.2]
Cholesterol (mg/dL)     175.0 [141.3-199.0]     165.5 [139.8-181.8]     156.5 [131.5-210.5]     163.0 [143.0-246.0]
Albumin (mg/dL) 4.2 [3.9-4.4] 4.3 [3.9-4.4] 4.2 [3.8-4.4] 4.2 [3.4-4.4]
LVEF < 40(%) 0   2 (14.3) 2 (6.9) 2 (28.6)
DM (%)   6 (28.6)   8 (57.1) 12 (41.4) 4 (57.1)
HTN (%) 17 (81.0) 12 (85.7) 19 (65.5) 5 (71.4)
COPD (%) 2 (9.5) 1 (7.1) 2 (6.9) 1 (14.3)
*P < 0.05, no AKI vs AKI in placebo group, 
†P < 0.05, no AKI vs AKI in EPO group, 
‡P < 0.05, EPO vs placebo group in patients with AKI. Descriptive statistics were reported as 
median values [25%-75%] for continuous variables. EPO, erythropoietin; AKI, acute kidney injury; BMI, body mass index; SBP, systolic blood pressure, DBP, diastolic blood pres-
sure; GFR, glomerular filtration rate; uNGAL, urinary neutrophil gelatinase-associated lipocalin; LVEF, left ventricular ejection fraction, DM, diabetes mellitus; HTN, hypertension; 
COPD, chronic obstructive pulmonary disease.
Table 2. Change of urine NGAL after coronary artery bypass grafting stratified by   
development of AKI
Group
Urine NGAL (ng/mL) after 
0 hr 2 hr 4 hr 24 hr 72 hr
Non-AKI 5.0
[2.2-14.2]
2.7
[1.8-8.3]
6.1
[2.5-14.0]
26.8
[17.6-91.0]
26.2
[11.4-51.3]
AKI 11.3*
[7.5-90.7]
12.0*
[6.5-89.0]
10.3*
[6.1-95.3]
 72.2*
[44.4-147.4]
 71.5*
[29.6-136.2]
Concentration of urine neutrophil gelatinase-associated lipocalin (NGAL) after coro-
nary artery bypass grafting was noted according to time changes in patients with acute 
kidney injury (AKI) and without AKI. Descriptive statistics were reported as median val-
ues [25%-75%] for continuous variables. *P < 0.05, AKI vs non-AKI group.Oh SW, et al.  •  Erythropoietin and Mortality in Acute Kidney Injury 
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AKI and the administration of EPO: group A, AKI in EPO group; 
group B, no AKI in placebo group; group C, no AKI in EPO group; 
group D, AKI in placebo group. Kaplan-Meier curves showed 
that a higher rate of mortality occurred in group D compared to 
that of groups A, B, and C (log-rank test, P = 0.022). Also, a higher 
composite outcome of mortality or ESRD occurred in group D 
compared to groups A, B, and C (log-rank test, P = 0.003) (Fig. 2). 
In patients who had AKI, the administration of EPO reduced 
the mortality and the composite outcome of mortality or ESRD.
DISCUSSION
We reported previously that pretreatment with EPO had a pro-
tective effect on AKI (8). We defined AKI in this study as an in-
crease in the serum Cr concentration of  ≥ 0.3 mg/dL from base-
line, a percentage increase in the serum Cr concentration of 
≥ 50% in the first 72 hr after CABG, or  < 0.5 mL/kg per hour of 
oliguria for more than six hours. We chose a 72-hr time point 
instead of a 48-hr time point, which is recommended by the 
AKI Network criteria (21). Because hemodilution occurs during 
cardiac surgery (22), a 72-hr time point has been chosen in clin-
ical studies of cardiac surgery (23, 24).
  First, we confirmed that pre-treatment of EPO reduced the 
incidence of AKI. It has been reported that EPO could improve 
AKI, neurocognitive dysfunction after cardiac surgery, left ven-
tricular ejection fraction after acute myocardial infarction, oxi-
dative stress, inflammation, and nutritional status in humans 
(5-9). In animal studies, EPO modulated apoptosis by decreas-
ing the ratio of Bax to Bcl-2 protein in the aorta (3). EPO also  
attenuates superoxide production and medial hyperplasia and 
restores the expression of endothelial nitric oxide synthase in 
nephrectomized rat aorta (4). Taken together, these results show 
that EPO has protective effects on inflammation, oxidative stress 
and apoptosis. 
  In contrast, higher death rate was reported in the EPO group 
compared with placebo group (25). Recently, randomized con-
trolled study reported no benefit of EPO on the outcome of AKI 
in patients with elevated two urinary markers in intensive care 
units (26). However, imperfect triaging into the intervention arm 
and heterogeneous timing of screening limits their results regard-
Table 3. Recovery from acute kidney injury after coronary artery bypass grafting
Group No.
Sex/age  
(yr)
Baseline Cr 
(mg/dL)
72-hr Cr  
(mg/dL)
2-week Cr 
[days]
‡ 
(mg/dL)
Placebo   1
  2
†
  3
†
  4
  5
  6
  7
  8
  9
10
11
12
13
14
F/75
M/75
F/72 
F/67
M/71
M/82
F/77
M/84
F/71
M/69
M/79
M/69
M/74
M/69
0.6
1.6
0.9
0.4
1.2
1.5
1.8
1.2
1.5
1.8
0.9
1.1
0.8
1.2
0.9
1.9
1
0.8
1.5
2.4
2.1
3.9
2.4
4.4
1.6
1.4
1.2
2.8
1.0 [14]
1.5 [13]
1.3 [13]
0.9 [13]
1.6 [13]
1.5 [14]
1.8 [11]
3.4 [14]
2.1 [19]
1.9 [14]
1.5 [14]
1.4 [16]
1.3 [12]
1.6 [14]
EPO   1
  2
  3
  4
  5
  6
  7
F/75
M/62
F/70
M/62
M/58
M/74
F/75
1.6
1.8
2
1.4
1.2
1.2
1
2.5
2.6
2.7
1.7
1.5
2.6
1.5
1.7 [14]
2.3 [14]
1.9 [11]
1.3 [13]
1.3 [13]
0.9 [14]
1.2 [14]
*P < 0.05, placebo group vs EPO group. 
†These patients met the urine output criteria 
of acute kidney injury. 
‡The measured time of 2-week Cr [days after coronary artery 
bypass grafting] was recorded. 72-hr Cr, Cr concentration 72 hr after coronary artery 
bypass grafting; 2-week Cr, Cr concentration 2 weeks after coronary artery bypass 
grafting; Cr, creatinine; EPO, erythropoietin.
Fig. 1. Changes of serum creatinine after coronary artery bypass grafting in patients 
with AKI. *P < 0.05 vs 0 days, both EPO and placebo group; 
†P < 0.05 vs 0 days, 
placebo group only. Error bars show the standard deviation of mean. 
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ing the efficacy of EPO.
  In our study, we found that EPO pre-treatment reduced mor-
tality or ESRD in patients with AKI, but it did not reduce mortal-
ity or ESRD in patients without AKI. We presumed that lower 
mortality in the EPO group might be due to a beneficial effect of 
EPO on recovery after AKI. We analyzed the comparison 2-week 
Cr to baseline Cr, and 72-hr Cr to baseline Cr to determine the 
severity and duration of AKI. In the EPO group, 2-week Cr was 
not different from baseline Cr. However, 2-week Cr in the pla-
cebo group was higher than baseline Cr. Although the extent of 
AKI 72 hr after CABG did not show any difference, renal func-
tion was recovered more easily in the EPO group than in the 
placebo group. This result might imply that EPO had a preven-
tive effect on AKI and thus enhanced the recovery after AKI. 
Therefore, EPO administration could be beneficial, at least in 
patients with high risk for AKI.
  NGAL has been known as a biomarker for the prediction of 
AKI (15, 16). NGAL levels are increased in bacterial infection, 
systemic disease and renal tubular injury. NGAL mRNA is syn-
thesized at high levels in the loop of Henle and collecting ducts 
in the ischemic kidney (18, 27). In previous reports, the concen-
tration of urine NGAL at 2 hr after cardiac surgery was the best 
predictor of AKI (15). Similarly, urine NGAL at 2 hr after CABG 
showed the highest AUC in our study. Although the AUC of base-
line urine NGAL was less than urine NGAL at 2 hr after CABG, 
the cutoff value of baseline urine NGAL 5 ng/mL yielded excel-
lent sensitivity and negative predictive values. However, depend-
ing on the definition of AKI, clinical setting, or measurement 
time, NGAL varies greatly with respect to cutoff and exhibits a 
low degree of specificity (16). Dysregulation of the NGAL bind-
ing protein that inhibits its degradation was found in type I dia-
betes (28). In addition, urine NGAL was also elevated in chronic 
kidney disease (CKD) as well as in AKI (29, 30). Also, we noticed 
that the baseline urine NGAL was significantly higher in patients 
with eGFR  < 60 mL/min/1.73 m
2 than those with eGFR  ≥ 60 
mL/min/1.73 m
2 (P = 0.002). Despite the association of urine 
NGAL and baseline renal function, urine NGAL at the baseline 
and 2 hr after CABG showed higher AUC values than baseline 
Cr (baseline urine NGAL, AUC 0.713 [95% CI 0.586-0.841]; urine 
NGAL at 2 hr, 0.804 [95% CI 0.696-0.911]; baseline Cr, 0.670 [95% 
CI 0.509-0.831]). Accordingly, urine NGAL might provide the 
better prediction of AKI than serum Cr at early time points, and 
the baseline urine NGAL could provide the additive informa-
tion to decide pretreatment with EPO. 
  Our study had several limitations. First, the wide variability of 
the baseline urine NGAL was noted in this study. This variabili-
ty could be attributed to the heterogeneity of patients, who had 
hypertension (75%), diabetes (42%), and baseline eGFR < 60 
mL/min/1.73 m
2 (26%). Second, small numbers of patients were 
included in this study. Third, the duration of the follow-up was 
short. Finally, the individual causes of death were not specified. 
  In spite of these limitations, our study has certain strengths. 
First, we determined that the long-term outcome could be im-
proved by EPO administration, largely due to beneficial effect 
of EPO on the recovery after AKI. Second, we assessed the value 
of baseline urine NGAL as a predictive marker of AKI in patients 
undergoing CABG. Further investigations with larger patient 
numbers of will be necessary to confirm our results.
  In conclusion, EPO reduces all-cause-mortality and ESRD in 
patients with AKI, largely due to the beneficial effect of EPO on 
recovery after AKI.
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